iProov Reports Record Year As Demand For Secure Online Identity Verification Soars
16.12.2021 10:00:00 EET | Business Wire | Press release
iProov, the world leader in biometric face authentication, today announced yet another record year of growth as global demand for online identity verification continues to soar.
iProov’s revenue for 2021 has tripled last year’s results, marking a major milestone for the company. During a single 10-day period in 2021, online verifications surpassed the number achieved in the whole of 2020. In addition, iProov delivered more than 1 million verifications in a single day several times throughout the year. To meet the increased demand for iProov’s award-winning services, the company increased staff by 64% across all business areas and geographies from December 2020 through December 2021, with a focus on adding even more new iProovers in 2022.
“iProov is giving people access to what is quickly becoming a basic human right: the ability to assert your identity online safely, securely and ubiquitously, with your privacy protected,” said Andrew Bud, Founder and CEO, iProov. “That higher mission is what drives everyone at iProov to work in such a focused and productive way. The result is a profitable year, ending with a very strong and robust cash position alongside many successful achievements across our business.”
2021 saw iProov continue to meet the rapidly scaling needs of large customers and partners around the globe. These included the Australian Taxation Office, which chose iProov’s Genuine Presence Assurance™ in March to enable Australians to set up their myGovID digital identity, providing access to services including managing tax returns, accessing health services and applying for benefits. Jumio, the leading provider of AI-powered end-to-end identity verification and eKYC solutions, added iProov’s Liveness Assurance and Genuine Presence Assurance to its platform to combat online crime and fraud worldwide. itsme, Belgium’s digital identity app, selected Genuine Presence Assurance to support its global expansion. And within the rapidly-evolving crypto space, Synaps, the Paris-based provider of digital identity services for cryptocurrency, also implemented Genuine Presence Assurance.
iProov closed out the year by working with Eurostar on the launch of a trial of its contactless fast-track travel service. SmartCheck enables passengers to complete secure ticket verification and UK exit check on their mobile devices prior to travel. Once at the station, passengers can choose to proceed through a dedicated SmartCheck lane with two face scans, eliminating the need to produce electronic or paper documentation.
2021 also saw an increase in demand for Genuine Presence Assurance in a variety of new applications and settings. iProov announced it is working with the National Science Foundation, University of Washington and MATTR to produce a flexible proof-of-concept technology to tackle the issue of verifying the source of online information and its reliability.
iProov also won a number of awards in 2021. These included recognition in the Deloitte Fast 50 of fastest-growing technology companies in the UK for the second year in a row and the naming of Andrew Bud as one of the Top 50 Most Ambitious Business Leaders. Earlier in 2021, iProov took home the highly regarded 2021 Global InfoSec Award for Biometrics Next-Gen, three Cybersecurity Excellence Awards and a Cyber Security Global Excellence Award for Best Biometric Solution.
“One of our values at iProov is that we ‘Achieve the Remarkable’ and we have certainly done that in 2021, in so many ways,” said Bud. “While we celebrate our achievements, we now look forward to the infinite opportunities and growth prospects that lie ahead for iProov in 2022.”
-Ends-
About iProov
Launched in 2013, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING, and others. iProov’s technologies include Liveness Assurance and Genuine Presence Assurance, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks and the emerging threat of deepfakes. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005936/en/
Contact information
Rob Tacey
rob.tacey@iproov.com
iProov
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Multi-Color Corporation Receives Court Approval of First Day Motions4.2.2026 22:30:00 EET | Press release
Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that it has received approval from the U.S. Bankruptcy Court for the District of New Jersey (the “Court”) for first day relief related to its prepackaged Chapter 11 filed on January 29, 2026. The approved relief affirms that the Company will operate in the normal course, pay all trade vendors and suppliers in full, and maintain a strong liquidity position during the restructuring. As part of this relief, the Court granted MCC immediate access to $125 million of $250 million in debtor-in-possession (“DIP”) new money financing, provided by certain holders of MCC’s secured first lien debt and its equity sponsor, CD&R. This funding will capitalize the business through the initial stages of the prepackaged Chapter 11 process. The Court also granted MCC authority to pay trade vendors and suppliers in full in the ordinary course, maintain wages and benefits without interruption, satisfy
InterSystems Honored with Four 2026 Best in KLAS Awards4.2.2026 19:00:00 EET | Press release
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has received four Global 2026 Best in KLAS awards. The company earned a #1 ranking for Acute Care EHR in Asia, Oceania, and France, as well as for Shared Care Records in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204241673/en/ InterSystems earns four Best in KLAS awards for 2026 Best in KLAS is KLAS Research’s annual recognition of top-performing healthcare technology and services solutions, based entirely on feedback from healthcare provider organizations. Awards are given within defined software and services market segments evaluated by KLAS Research using a standardized methodology that reflects customer experience and performance. In addition to U.S. market segments, KLAS also recognizes top-performing solutions through its Global (Non-U.S.) Best in KLAS Awards, which are based on fe
Onego Bio Strengthens Board with Appointment of Dr. Antti Vasara4.2.2026 17:00:00 EET | Press release
Onego Bio, the food ingredient company producing non-animal egg protein through precision fermentation, today announced that Dr. Antti Vasara has joined its board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204881159/en/ Dr. Antti Vasara Dr. Vasara brings more than 25 years of global experience in science, technology, and commercial strategy. Most recently, he served as President and CEO of VTT Technical Research Centre of Finland, where he led one of Europe’s foremost deep tech research organizations. His distinguished career spans senior leadership roles in industry and innovation policy—including impactful work with Nokia and strategic contributions to European research and development initiatives. “Antti is one of the most respected leaders in science and innovation,” said Maija Itkonen, CEO of Onego Bio. “His deep understanding of technology commercialization and ecosystem level strategy will be inva
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
